AMERICAN JOURNAL OF HEMATOLOGY
Scope & Guideline
Pioneering Insights for Tomorrow's Hematology
Introduction
Aims and Scopes
- Hematological Malignancies:
The journal extensively covers research on leukemia, lymphoma, and myeloma, focusing on novel therapies, clinical trials, and molecular genetics that influence treatment and prognosis. - Transfusion Medicine:
Research related to transfusion practices, blood safety, and the management of transfusion-related complications is a key area, reflecting the journal's commitment to improving patient care in transfusion settings. - Sickle Cell Disease and Thalassemia:
Papers often explore the pathophysiology, management strategies, and innovative therapies for sickle cell disease and thalassemia, aiming to improve health outcomes for affected individuals. - Coagulation Disorders:
The journal includes research on various coagulation disorders, including hemophilia and thrombosis, focusing on new treatment modalities and strategies for management. - Stem Cell Transplantation:
There is a significant emphasis on studies related to hematopoietic stem cell transplantation, including donor selection, conditioning regimens, and post-transplant outcomes. - Clinical Trials and Therapeutics:
The journal publishes findings from clinical trials of new drugs, treatment regimens, and innovative therapies, contributing to the evidence base for clinical practice.
Trending and Emerging
- Immunotherapy and CAR-T Cell Therapy:
There is a growing emphasis on the development and application of immunotherapies, particularly CAR-T cell therapies, for hematological malignancies, showcasing innovative treatment options. - Targeted Therapy and Precision Medicine:
Research focusing on targeted therapies based on genetic and molecular profiling of hematological disorders is on the rise, reflecting a shift towards personalized treatment approaches. - Biomarkers and Minimal Residual Disease Monitoring:
Emerging studies are increasingly focusing on the identification and utilization of biomarkers for disease monitoring and prognosis, particularly in acute myeloid leukemia and other malignancies. - Health Disparities and Patient-Centered Care:
The journal is increasingly addressing health disparities within hematology, emphasizing the importance of equitable care and patient-reported outcomes in treatment strategies. - Long-term Effects of COVID-19 on Hematology Patients:
Research exploring the implications of COVID-19 on patients with existing hematological conditions, including vaccine responses and management challenges, has gained prominence. - Artificial Intelligence and Machine Learning in Hematology:
There is a notable trend towards integrating artificial intelligence and machine learning into hematology research, particularly in diagnostics and treatment personalization.
Declining or Waning
- Traditional Chemotherapy Approaches:
There is a noticeable decrease in studies focusing solely on traditional chemotherapy regimens as the field moves towards targeted therapies and immunotherapies, which are now the focus of many clinical trials. - Basic Science Research:
The journal has shifted towards more clinically relevant studies, with a waning interest in purely basic science research that does not directly translate to clinical applications. - Epidemiological Studies:
Although still important, there appears to be a reduction in the volume of studies that solely focus on the epidemiology of hematological disorders, as the emphasis shifts towards treatment outcomes and therapeutic innovations. - Longitudinal Studies in Hematology:
Fewer longitudinal studies are being published, as funding and interest may be shifting towards more immediate, impactful clinical trials and translational research.
Similar Journals
Hematology Transfusion and Cell Therapy
Innovating the future of blood disorder management.Hematology Transfusion and Cell Therapy, published by Elsevier, is a leading Open Access journal dedicated to advancing the fields of hematology, immunology, and transfusion medicine. Since its establishment in 2018, this journal has provided a vital platform for sharing innovative research and clinical advancements in the management of blood disorders and cellular therapies. Based in Brazil, it attracts a global audience, facilitating access to high-quality research that influences clinical practice and policy. With a current impact factor that places it in the Q3 category for both hematology and immunology as of 2023, the journal is recognized for its rigorous peer-review process and commitment to disseminating significant findings. By featuring a diverse range of articles, from original research to reviews, Hematology Transfusion and Cell Therapy aims to foster collaboration and knowledge sharing among researchers, professionals, and students alike, empowering them to tackle emerging challenges in their fields.
BRITISH JOURNAL OF HAEMATOLOGY
Delivering High-Impact Research for Clinical ExcellenceBritish Journal of Haematology, published by Wiley, is a leading journal in the field of hematology, with an impressive impact factor reflecting its significance in the medical research community. Established in 1955, the journal has consistently contributed to advancing knowledge in hematology, currently holding a prestigious Q1 ranking in the Scopus category of Hematology, placing it in the top 18% of the field. The journal encompasses a broad range of topics including clinical and laboratory aspects of blood disorders and hematological malignancies, making it an essential resource for hematologists, researchers, and healthcare professionals. With its commitment to publishing top-tier research and clinical studies, the British Journal of Haematology plays a critical role in shaping treatment approaches and improving patient outcomes worldwide. Please note that this journal does not offer Open Access options, ensuring that published content is rigorously curated for quality and relevance.
BLOOD REVIEWS
Pioneering insights into blood health and disease.BLOOD REVIEWS is a highly regarded journal published by Churchill Livingstone, specializing in the fields of Hematology and Oncology. With an impressive Q1 ranking in both disciplines and placing in the top 10% of its peer categories according to Scopus metrics, it provides an essential platform for the dissemination of cutting-edge research and reviews pertaining to blood disorders and cancer treatment. Since its inception in 1987 and continuing through 2024, the journal has established itself as a cornerstone for healthcare professionals, researchers, and students who seek to advance their understanding of hematologic and oncologic topics. While not an open-access journal, BLOOD REVIEWS retains a reputation for delivering high-quality, peer-reviewed articles that foster dialogue and innovation within the scientific community. For those in the United States and beyond, the journal serves as a vital resource, housed at the Journal Production Department in Edinburgh, Scotland, ensuring accessibility and a global reach in its critical academic contributions.
Egyptian Journal of Haematology
Connecting Scholars to Transform Hematology PracticeThe Egyptian Journal of Haematology, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of hematology, particularly within the context of Egypt and the broader Middle Eastern region. This journal is dedicated to disseminating high-quality research that explores the latest advancements in blood disorders, hematologic malignancies, and transfusion medicine. With a focus on original research, case studies, and reviews, it aims to provide a comprehensive platform for hematologists, researchers, and healthcare professionals to enhance their understanding and management of hematological conditions. Although it is not an open-access journal, the rigorous peer-review process ensures that only the most impactful studies are published, contributing to the journal's reputation in the academic community. The Egyptian Journal of Haematology serves as an essential tool for advancing knowledge, improving clinical outcomes, and fostering collaboration among experts in the field.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
Innovating treatment pathways for young patients.JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, published by Lippincott Williams & Wilkins, serves as a vital platform for the dissemination of cutting-edge research and insights in the fields of pediatric hematology and oncology. Since its inception in 1979, the journal has maintained a commitment to advancing knowledge through peer-reviewed articles that contribute to the understanding and treatment of blood disorders and cancers in children. With an impact factor reflective of its academic contributions, the journal is positioned in the Q3 quartile across key medical categories — Hematology, Oncology, and Pediatrics, Perinatology and Child Health — indicating its relevance and influence in the field. While it does not currently offer open access options, the journal remains a crucial resource for researchers, clinicians, and students dedicated to improving pediatric care and outcomes. Researchers are encouraged to contribute to this esteemed journal as it seeks to bridge the gap between clinical practice and research, fostering innovation and improved quality of life for young patients affected by hematologic and oncologic conditions.
Asian Journal of Transfusion Science
Elevating patient care through innovative research.Asian Journal of Transfusion Science, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, is a prominent open-access journal dedicated to the interdisciplinary fields of hematology and immunology. With an ISSN of 0973-6247 and E-ISSN 1998-3565, it serves as a crucial platform for researchers, clinicians, and students from around the globe, facilitating the dissemination of high-quality, peer-reviewed research. Established in 2007, the journal has consistently aimed to advance scientific knowledge in transfusion practices, enhancing patient care and safety in transfusion medicine. Despite its recent categorization in the Q4 quartile within both Hematology and Immunology, the journal is making strides toward greater visibility in the academic community, with plans for expanded reach and increased citation impact. With its commitment to open-access publishing, the Asian Journal of Transfusion Science ensures that invaluable research findings are readily accessible to all stakeholders, thereby bolstering collaborative efforts in transfusion science and related disciplines.
Journal of Hematology
Bridging Knowledge Gaps in HematologyThe Journal of Hematology, published by ELMER PRESS INC, serves as a pivotal platform for disseminating cutting-edge research in the field of hematology. With an ISSN of 1927-1212 and an E-ISSN of 1927-1220, this journal is committed to advancing scientific knowledge and clinical practice through high-quality peer-reviewed articles encompassing all aspects of blood disorders, from basic science to health policy implications. While the journal currently operates under a traditional access model, it nonetheless prioritizes the rapid publication of significant findings, ensuring that researchers, clinicians, and students have timely access to the latest advancements in hematological research. Positioned to bridge gaps in knowledge and foster collaboration among scholars worldwide, the Journal of Hematology is an essential resource for anyone invested in this vital area of medicine.
TRANSFUSION MEDICINE AND HEMOTHERAPY
Exploring breakthroughs in hemotherapy and patient care.TRANSFUSION MEDICINE AND HEMOTHERAPY, published by KARGER, is a prominent journal dedicated to advancing the fields of hematology and transfusion medicine. With an ISSN of 1660-3796 and E-ISSN 1660-3818, this esteemed journal has been a valuable resource for researchers and clinicians since its inception in 1973, with significant publication phases continuing into 2024. It currently holds a Q2 ranking in Hematology and a Q3 ranking in Immunology and Allergy, reflecting its impact and relevance in these critical fields. The journal features original articles, reviews, and clinical studies, presenting cutting-edge research that aids in the development of effective therapies and enhances patient care. Open access options are available, ensuring that crucial findings are accessible to a broad audience. As an important platform for dialogue and advancement in transfusion science, TRANSFUSION MEDICINE AND HEMOTHERAPY supports the global health community's efforts to improve treatment outcomes and foster innovation in medical practices.
EUROPEAN JOURNAL OF HAEMATOLOGY
Bridging Science and Practice in Blood Disorder ManagementEUROPEAN JOURNAL OF HAEMATOLOGY, published by Wiley, serves as a vital resource for experts in the field of hematology, focusing on the latest advancements in blood disorders and therapies. With an ISSN of 0902-4441 and an E-ISSN of 1600-0609, this esteemed journal has been disseminating knowledge since 1986 and continues to thrive, converging its visionary approach through to 2024. Notably, it holds a distinguished Q2 ranking in Hematology and an impressive Q1 ranking in the broader category of Medicine (miscellaneous) as of 2023, highlighting its significant contribution to the scientific community. With a Scopus rank of #45/137 and a 67th percentile in the field, the journal is recognized for its rigorous peer-reviewed research, making it an indispensable publication for researchers, practitioners, and students aiming to stay at the forefront of hematological studies. Though not an open-access journal, it ensures broad accessibility to critical findings via its subscription model, thus fostering an informed and globally engaged audience.
TRANSFUSION AND APHERESIS SCIENCE
Bridging Theory and Practice in Transfusion and ApheresisTRANSFUSION AND APHERESIS SCIENCE, published by Pergamon-Elsevier Science Ltd, serves as a pivotal platform for researchers and practitioners in the fields of hematology, transfusion medicine, and apheresis. With an ISSN of 1473-0502 and an E-ISSN of 1878-1683, this peer-reviewed journal boasts a respectable Q3 ranking in the Hematology category as of 2023, positioning it within the 45th percentile among its counterparts. Operating from the United Kingdom, it provides comprehensive insights into the latest advancements and methodologies in transfusion practices and apheresis technology, crucial for enhancing patient care and therapeutic strategies. The journal's scope, covering key developments from 1996 to 2024, allows for a deep exploration of historical and emerging trends within the discipline. Moreover, its open access options facilitate widespread dissemination of research findings, fostering collaboration and innovation in the scientific community. For those dedicated to advancing knowledge in hematology, TRANSFUSION AND APHERESIS SCIENCE represents an essential resource, bridging theory and practice in this vital area of healthcare.